Azercabtagene zapreleucel is under clinical development by Imugene and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for Non-Hodgkin Lymphoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Azercabtagene zapreleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Azercabtagene zapreleucel overview
Azercabtagene zapreleucel (PBCAR-0191) is under development for the treatment of graft vs host disease, relapsed or refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma including diffuse large B cell lymphoma, follicular lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma, high grade B cell lymphoma and autoimmune disorders. It is administered through intravenous route. The therapeutic candidate constitutes of allogenic anti-CD19 chimeric antigen receptor (CAR) T cells. It is developed based on the ARCUS technology platform. It is a genome editing platform derived from a natural genome editing enzyme called homing endonuclease which incorporates Adeno-associated virus (AAV) vector. It acts by targeting cells expressing the CD19 protein.
Imugene overview
Imugene is a clinical-stage biopharmaceutical company that focuses on the development of vaccines in the area of oncology. The company develops immunotherapies that activate the immune system of cancer patients to identify and eradicate tumors. The company develops products for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for the treatment of mixed advanced solid tumors (MAST) and metastatic triple-negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales Australia.
For a complete picture of Azercabtagene zapreleucel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
